ADAR1 Capital Management LLC Has $83,000 Stake in GlycoMimetics, Inc. (NASDAQ:GLYC)

Posted by Casey Walker on Apr 8th, 2025

ADAR1 Capital Management LLC raised its holdings in GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 626.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 331,827 shares of the biotechnology company’s stock after buying an additional 286,127 shares during the period. ADAR1 Capital Management LLC owned 0.51% of GlycoMimetics worth $83,000 at the end of the most recent reporting period.

Separately, Wellington Management Group LLP bought a new position in shares of GlycoMimetics in the 4th quarter valued at about $352,000. Hedge funds and other institutional investors own 75.19% of the company’s stock.

GlycoMimetics Price Performance

Shares of GLYC opened at $0.18 on Tuesday. The firm has a 50-day moving average of $0.26 and a 200-day moving average of $0.26. GlycoMimetics, Inc. has a one year low of $0.14 and a one year high of $2.81.

GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. As a group, analysts expect that GlycoMimetics, Inc. will post -0.08 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. StockNews.com initiated coverage on GlycoMimetics in a report on Monday. They set a “sell” rating on the stock. Cantor Fitzgerald initiated coverage on GlycoMimetics in a research note on Friday, March 21st. They set an “overweight” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Get Our Latest Research Report on GLYC

About GlycoMimetics

(Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.